X0202 SCHEDULE 13G/A 0000935836-26-000092 0001440771 XXXXXXXX LIVE 2 Common Stock 03/31/2026 0001729427 CNS Pharmaceuticals, Inc. 18978H508 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 Rule 13d-1(c) Stonepine Capital Management, LLC b DE 0.00 159790.00 0.00 159790.00 159790.00 N 9.9 IA OO The shares of the Common Stock reported herein consist of 21,738 shares of Common Stock and warrants to purchase 1,304,348 shares of Common Stock, subject to a 9.99% beneficial ownership limitation, held by the Reporting Persons as of the date of this report. Percentage calculated based on 1,461,449 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026. Stonepine Capital, L.P. b DE 0.00 159790.00 0.00 159790.00 159790.00 N 9.9 PN The shares of the Common Stock reported herein consist of 21,738 shares of Common Stock and warrants to purchase 1,304,348 shares of Common Stock, subject to a 9.99% beneficial ownership limitation, held by the Reporting Persons as of the date of this report. Percentage calculated based on 1,461,449 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026. Stonepine GP, LLC b DE 0.00 159790.00 0.00 159790.00 159790.00 N 9.9 OO The shares of the Common Stock reported herein consist of 21,738 shares of Common Stock and warrants to purchase 1,304,348 shares of Common Stock, subject to a 9.99% beneficial ownership limitation, held by the Reporting Persons as of the date of this report. Percentage calculated based on 1,461,449 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026. Jon M. Plexico b X1 0.00 159790.00 0.00 159790.00 159790.00 N 9.9 HC IN The shares of the Common Stock reported herein consist of 21,738 shares of Common Stock and warrants to purchase 1,304,348 shares of Common Stock, subject to a 9.99% beneficial ownership limitation, held by the Reporting Persons as of the date of this report. Percentage calculated based on 1,461,449 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026. CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900, Houston, TX 77027 Stonepine Capital Management, LLC, a Delaware limited liability company ("Stonepine") Stonepine Capital, L.P., a Delaware limited partnership (the "Partnership") Stonepine GP, LLC, a Delaware limited liability company (the "General Partner") Jon M. Plexico Stonepine and the General Partner are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and the General Partner. The reporting persons are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of Ordinary Shares except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Ordinary Shares covered by this Schedule 13G. 2900 NW Clearwater Drive, Suite 100-11, Bend OR 97703 See Item 4 of the cover sheet for each reporting person. Y Stonepine: 159,790 Partnership: 159,790 General Partner: 159,790 Jon M. Plexico: 159,790 Stonepine: 9.9% Partnership: 9.9% General Partner: 9.9% Jon M. Plexico: 9.9% Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0 Stonepine: 159,790 Partnership: 159,790 General Partner: 159,790 Jon M. Plexico: 159,790 Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0 Stonepine: 159,790 Partnership: 159,790 General Partner: 159,790 Jon M. Plexico: 159,790 Y N The Partnership holds Common Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. EXHIBIT 99 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G Stonepine Capital Management, LLC /s/ Jon M. Plexico 05/15/2026 Stonepine Capital, L.P. /s/ Jon M. Plexico 05/15/2026 Stonepine GP, LLC /s/ Jon M. Plexico 05/15/2026 Jon M. Plexico /s/ Jon M. Plexico 05/15/2026